Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression

by Neurology Live
0 Comments
0 Mins
Serum NPTX2 emerges as a novel biomarker in ALS, with combined NPTX2 and NfL levels improving survival prediction and disease monitoring.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Do SDOH Drive Survival Outcomes With Brexu-Cel in ALL?
Next Post
Global Burden of MASH-Related Liver Cancer Rising Sharply Among Older Adults
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago